Compare ANGH & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGH | BCTX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United Arab Emirates | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 36.6M |
| IPO Year | 2021 | 2025 |
| Metric | ANGH | BCTX |
|---|---|---|
| Price | $3.44 | $3.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.6K | ★ 62.6K |
| Earning Date | 12-29-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $251.30 | N/A |
| Revenue Next Year | $26.67 | $250.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $2.60 |
| 52 Week High | $7.89 | $13.09 |
| Indicator | ANGH | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 50.00 |
| Support Level | $3.12 | $3.50 |
| Resistance Level | $3.89 | $3.74 |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 54.75 | 53.98 |
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.